Chemical formula: C₂₂H₂₂F₃N Molecular mass: 357.412 g/mol PubChem compound: 156419
Cinacalcet is a calcimimetic agent which directly lowers PTH levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| H05BX01 | Cinacalcet | H Systemic hormonal preparations, excl. Sex hormones and insulins → H05 Calcium homeostasis → H05B Anti-parathyroid agents → H05BX Other anti-parathyroid agents |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| MIMPARA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| SENSIPAR Coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Cinacalcet is an active ingredient of these brands:
United States (US)
Brazil (BR)Canada (CA)
Croatia (HR)
Ecuador (EC)Estonia (EE)
France (FR)
Hong Kong (HK)
Ireland (IE)
Italy (IT)
Japan (JP)
Lithuania (LT)
Mexico (MX)
Netherlands (NL)
New Zealand (NZ)
Romania (RO)
Singapore (SG)
South Africa (ZA)
Spain (ES)
Turkey (TR)United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
